Novavax/$NVAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
- Ticker
- $NVAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 749
- Headquarters
- Gaithersburg, United States
- Website
- www.novavax.com
Novavax Metrics
BasicAdvanced
$1.7B
-
-$1.52
2.42
-
Price and volume
Market cap
$1.7B
Beta
2.42
52-week high
$13.39
52-week low
$6.20
Average daily volume
7.9M
Financial strength
Current ratio
2.333
Quick ratio
2.233
Long term debt to equity
-1.537
Total debt to equity
-1.559
Interest coverage (TTM)
-5.20%
Profitability
EBITDA (TTM)
-101.552
Gross margin (TTM)
-2.56%
Net profit margin (TTM)
-59.87%
Operating margin (TTM)
-28.85%
Effective tax rate (TTM)
-0.98%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-6.51%
Return on equity (TTM)
323.66%
Valuation
Price to revenue (TTM)
4.129
Price to book
-9.05
Price to tangible book (TTM)
-5.69
Price to free cash flow (TTM)
-39.711
Free cash flow yield (TTM)
-2.52%
Free cash flow per share (TTM)
-0.264
Growth
Revenue change (TTM)
-61.64%
Earnings per share change (TTM)
-159.61%
3-year revenue growth (CAGR)
-36.25%
10-year revenue growth (CAGR)
36.01%
3-year earnings per share growth (CAGR)
-40.03%
10-year earnings per share growth (CAGR)
-22.68%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Analyst projections of the future price of Novavax stock.
Bulls say / Bears say
Updated Nuvaxovid vaccines were approved for the 2026–27 season in the US, EU and Japan, while Sanofi is expanding marketing and launches into additional countries. That gives Novavax a route to royalty income without running its own sales operation. (Novavax)
Pfizer has licensed Matrix-M for vaccine development, with up to $500 million in potential milestones and royalties, and other pharmaceutical companies are evaluating the technology. These agreements could broaden Novavax’s income beyond its COVID vaccine. (Novavax)
In a 1,000-person Phase 4 study, Nuvaxovid had statistically lower systemic side effects than Moderna’s mNEXSPIKE across the pre-specified measures. This may help distinguish it when patients and clinicians choose a COVID vaccine. (Sanofi)
Novavax remains exposed to weak COVID vaccine demand, and Reuters reports that it is relying largely on Sanofi licensing revenue to reach its 2028 profitability goal. Lower uptake could therefore constrain the royalty stream central to its recovery. (Reuters)
Novavax used $105.2 million of cash in operating activities in the first half of 2026 and reported a $62.9 million net loss for the period. Its substantial cash balance helps, but ongoing losses make cost cuts and future partner income important. (U.S. Securities and Exchange Commission)
Some sizeable expected partner payments remain conditional: Sanofi’s $125 million milestone depends on starting a Phase 3 combination-vaccine trial, while a further $75 million depends on completing a manufacturing transfer expected in mid-2027. Delays would push out cash that Novavax is counting on for its longer-term plan. (Novavax)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novavax News
AllArticlesVideos
Funds containing Novavax
Fund name | Fund size | $NVAX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.16% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.